Data for evaluating drugs is often poor, say experts

doi:10.1136/bmj.330.7498.984-d

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ research articles:

From

Limit by

This article has a correction

Please see: Regulator restricts use of SSRIs in children

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Bob Roehr

Washington DC

Evidence based medicine is moving from relatively simple questions about a drug's safety and effectivenesss to thornier questions of relative clinical effectiveness and cost effectiveness, international experts agreed at a meeting last week. The experts, from the United States, Canada, the United Kingdom, and Germany, had assembled to discuss these issues with congressional and policy staff in Washington, DC.

“While there is a lot of data out there, unfortunately it is often very poor,” said Dr Peter Littlejohns, director of the UK's National Institute for Health and Clinical Excellence. …